Precision medicine for Parkinson's disease with comorbidities

Abstract

Parkinson's disease (PD) is a chronically progressive neurodegenerative disease with a prevalence of about 100 to 180 per 100,000 in Japan, which is increasing with aging. Focusing on the Parkinson's disease clinical practice guideline 2018 supervised by the Japanese Society of Neurology, we will outline the drug treatment algorithm in early and advanced PD and the points to be noted in drug treatment in PD patients with comorbidities.